ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Endocrinology, Diabetes Metabolism

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

15,484Medicare Part D Prescriptions Filled, Including Refills

Rank: 2 out of 120

$2M Total Retail Price of All Prescriptions

Rank: 1 out of 120

776 Patients Receiving at Least One Drug in Part D
70%Patients 65 Years and Older
44% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in North Carolina
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

5% of this provider’s 776 patients filled at least one prescription for a schedule three drug, compared to an average of 2%.

Risky Drugs to Seniors

2% of this provider’s 10,865 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

57% of this provider’s prescriptions were for brand-name drugs, compared to an average of 49%.

Prescription Price

$129 was the average price of a prescription from this provider, compared to $124 among peers.

Prescriptions per Patient

20 is the average number of prescriptions (including refills) per patient, compared to an average of 11.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in North Carolina
SYNTHROID 1,988 1,339 1 1
SIMVASTATIN 738 545 2 8
LANTUS 636 455 3 7
HUMALOG 600 461 10 4 9
LANTUS SOLOSTAR 478 320 5 5
PEN NEEDLE 444 263 6 4
AMLODIPINE BESYLATE 403 319 7 17
CARVEDILOL 393 299 8 36
LOSARTAN POTASSIUM 392 309 9 23
INSULIN SYRINGE 385 261 10 12
ACTOS 334 270 11 24
FUROSEMIDE 329 227 12 21
METFORMIN HCL 309 246 13 3
METFORMIN HCL ER 289 160 14 6
GLIPIZIDE ER 281 226 15 41
JANUMET 252 170 16 44
VYTORIN 224 163 17 62
NOVOLOG FLEXPEN 218 106 18 11
JANUVIA 217 180 19 18
LISINOPRIL 205 147 20 14
FENOFIBRATE 197 116 21 31
CRESTOR 178 139 22 20
ATORVASTATIN CALCIUM 177 130 23 19
LOSARTAN-HYDROCHLOROTHIAZIDE 172 128 24 35
NOVOLOG 170 94 25 16
ZETIA 161 74 26 40
LEVOTHYROXINE SODIUM 160 86 27 2
PIOGLITAZONE HCL 159 123 R 28 56
PRAVASTATIN SODIUM 157 116 29 22
ENALAPRIL MALEATE 146 102 30 76
ALENDRONATE SODIUM 136 122 31 29
APIDRA 132 89 10 32 114
GLIPIZIDE XL 130 96 33 67
BYSTOLIC 130 91 33 115
LEVOXYL 122 109 35 15
HYDROCHLOROTHIAZIDE 122 97 35 25
ATELVIA 103 84 37 124
ANDROGEL 102 64 S3 38 81
LOVAZA 96 47 39 54
BENICAR 94 87 40 108
GLIMEPIRIDE 92 80 41 10
GABAPENTIN 90 66 42 26
WELCHOL 89 57 43 98
TRIBENZOR 89 80 43 125
TRILIPIX 86 34 45 69
AZOR 84 74 46 113
ACTOPLUS MET 82 60 47 129
HYDROCORTISONE 80 59 48 48
HUMULIN N 80 58 48 47
BENICAR HCT 71 59 50 112
BYETTA 71 51 50 30
METOPROLOL SUCCINATE 70 59 52 37
KOMBIGLYZE XR 67 42 53 105
OMEPRAZOLE 65 41 54 32
HUMULIN R 59 30 55 28
SPIRONOLACTONE 55 26 56 105
IBANDRONATE SODIUM 54 53 57 121
CLONIDINE HCL 53 48 58 46
ONGLYZA 53 31 58 51
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on June 30, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.